PMID- 25346147
OWN - NLM
STAT- MEDLINE
DCOM- 20150123
LR  - 20141127
IS  - 1365-3083 (Electronic)
IS  - 0300-9475 (Linking)
VI  - 80
IP  - 6
DP  - 2014 Dec
TI  - Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult 
      patients with acute myeloid leukaemia.
PG  - 424-31
LID - 10.1111/sji.12223 [doi]
AB  - Dendritic cells (DCs) develop in the bone marrow from haematopoietic progenitor 
      cells. Two subsets, plasmacytoid DCs (pDCs) and myeloid DCs (mDCs), have been 
      identified. Little is known regarding DC levels in bone marrow of patients with 
      acute myeloid leukaemia (AML) before and after chemotherapy. We investigated 
      relative pDC and mDC levels in bone marrow from 37 hospital controls and 60 
      patients with AML [at diagnosis, complete remission (CR) and follow-up] using 
      four-colour flow cytometry. The pDC immunophenotype was characterized as 
      lin-/HLA-DR+/CD123 +  and mDC as lin-/HLA-DR+/CD11c+. In 69% of patients with 
      AML, no DCs were detected at diagnosis. At CR, mDC levels were the same in 
      patients with AML and hospital controls while pDC levels were slightly lower. 
      There was no association between minimal residual disease or survival rates and 
      DC levels. Patients with low mDC levels at CR were more likely to suffer from 
      complicated infections, although the difference was not statistically 
      significant. Altogether, there was a profound decrease in DC levels in patients 
      with AML at diagnosis. DC levels increased at CR and were higher than in hospital 
      controls after post-remission therapy, suggesting that DCs recover after repeated 
      chemotherapy. There may be an association between mDC levels and infectious 
      complications.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Derolf, A R
AU  - Derolf AR
AD  - Division of Hematology, Department of Medicine, Karolinska University Hospital 
      Solna and Karolinska Institutet, Stockholm, Sweden.
FAU - Laane, E
AU  - Laane E
FAU - Bjorklund, E
AU  - Bjorklund E
FAU - Saft, L
AU  - Saft L
FAU - Bjorkholm, M
AU  - Bjorkholm M
FAU - Porwit, Anna
AU  - Porwit A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Marrow/*pathology
MH  - Case-Control Studies
MH  - Cell Count
MH  - Dendritic Cells/immunology/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunophenotyping
MH  - Leukemia, Myeloid, Acute/drug therapy/*metabolism/mortality/*pathology
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Monocytes/metabolism
MH  - Neoplasm, Residual
MH  - Recurrence
MH  - Remission Induction
MH  - Young Adult
EDAT- 2014/10/28 06:00
MHDA- 2015/01/24 06:00
CRDT- 2014/10/28 06:00
PHST- 2014/02/13 00:00 [received]
PHST- 2014/08/12 00:00 [accepted]
PHST- 2014/10/28 06:00 [entrez]
PHST- 2014/10/28 06:00 [pubmed]
PHST- 2015/01/24 06:00 [medline]
AID - 10.1111/sji.12223 [doi]
PST - ppublish
SO  - Scand J Immunol. 2014 Dec;80(6):424-31. doi: 10.1111/sji.12223.